The market is rewarding platforms that promise to rewrite instructions rather than merely manage symptoms. Eli Lilly and Company (LLY) is teaming up with privately held Ascidian Therapeutics in a deal valued at up to $1.9 billion, giving Lilly exclusive, target-specific rights…